The impact of microenvironmental heterogeneity on the evolution of drug resistance in cancer cells

Cancer Informatics

Volumn 14, Issue , 2015, Pages 19-31

  Mumenthaler, Shannon M ^a   Foo, Jasmine ^b   Choi, Nathan C ^a   Heise, Nicholas ^b   Leder, Kevin ^c   Agus, David B ^a   Pao, William ^d   Michor, Franziska ^e,f   Mallick, Parag ^g  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b School of Mathematics   (United States)

^c University of Minnesota   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e Department of Biostatistics and Computational Biology Dana Farber Cancer Institute   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g STANFORD UNIVERSITY   (United States)

Author keywords

Cancer; Drug resistance; Evolutionary modeling; Microenvironment

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GLUCOSE; OXYGEN;

ARTICLE; CANCER RECURRENCE; CELL COMPARTMENTALIZATION; CELL COUNT; CELL DEATH; CELL GROWTH; CELL SURVIVAL; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; MATHEMATICAL MODEL; NON SMALL CELL LUNG CANCER; NUTRIENT CONTENT; PREDICTION; QUANTITATIVE ANALYSIS; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

EID: 84937400567     PISSN: None     EISSN: 11769351     Source Type: Journal    
DOI: 10.4137/CIN.S19338     Document Type: Article

References (73)

1. Sawyers C. Targeted cancer therapy. Nature. 2004;432:294–7.
2. Ellis LM, Hicklin DJ. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin Cancer Res. 2009;15:7471–8.
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.
4. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clinical cancer research. 2009;15:7479–91.
5. Haber DA, Bell DW, Sordella R, et al. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb Symp Quant Biol. 2005;70:419–26.
6. Pérez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer. J Clin Oncol. 2004;22:3238–47.
7. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–500.
8. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73.
9. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039–43.
10. Heppner GH. Tumor heterogeneity. Cancer Res. 1984;44:2259–65.
11. Gerlinger M, Rowan AJ, Horswell S. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92.
12. Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486:537–40.
13. Kreso A, O’Brien CA, van Galen P, et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science. 2013;339:543–548.
14. Gatenby RA, Smallbone K, Maini PK, et al. Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer. 2007;97:646–53.
15. Casciari JJ, Sotirchos SV, Sutherland RM. Variations in tumor cell growth rates and metabolism with oxygen concentration, glucose concentration, and extracellular pH. J Cell Physiol. 1992;151:386–94.
16. Fang JS, Gillies RD, Gatenby RA. Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin Cancer Biol. 2008;18:330–7.
17. Straussman R, Morikawa T, Shee K. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487:500–4.
18. Patel AA, Gawlinski ET, Lemieux SK, Gatenby RA. A cellular automaton model of early tumor growth and invasion. J Theor Biol. 2001;213:315–31.
19. Gatenby RA, Gillies RJ. A microenvironmental model of carcinogenesis. Nat Rev Cancer. 2008;8:56–61.
20. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432:332–7.
21. Mueller MM, Fusenig NE. Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells. Differentiation. 2002;70:486–97.
22. Frank SA. Somatic mosaicism and cancer: inference based on a conditional Luria-Delbruck distribution. J Theor Biol. 2003;223:405–12.
23. Skipper HE. The forty-year-old mutation theory of Luria and Delbruck and its pertinence to cancer chemotherapy. Adv Cancer Res. 1983;40:331–63.
24. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315:550–4.
25. Komarova NL, Wodarz D. Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci U S A. 2005;102:9714–9.
26. Komarova N. Stochastic modeling of drug resistance in cancer. J Theor Biol. 2006;239:351–66.
27. Komarova NL, Wodarz D. Stochastic modeling of cellular colonies with quiescence: an application to drug resistance in cancer. Theor Popul Biol. 2007;72:523–38.
28. Coldman AJ, Goldie JH. A stochastic model for the origin and treatment of tumors containing drug-resistant cells. Bull Math Biol. 1986;48:279–92.
29. Harnevo LE, Agur Z. Drug resistance as a dynamic process in a model for multistep gene amplification under various levels of selection stringency. Cancer Chemother Pharmacol. 1992;30:469–76.
30. Harnevo LE, Agur Z. The dynamics of gene amplification described as a multitype compartmental model and as a branching process. Math Biosci. 1991;103:115–38.
31. Durrett R, Moseley S. Evolution of resistance and progression to disease during clonal expansion of cancer. Theor Popul Biol. 2010;77:42–8.
32. Swan GW. Optimization of Human Cancer Radiotherapy. Berlin: Springer; 1981.
33. Birkhead BG, Rankin EM, Gallivan S, Dones L, Rubens RD. A mathematical model of the effects of drug resistance in cancer chemotherapy. Math Biosci. 1984;72:59–69.
34. Panetta JC. A mathematical model of periodically pulsed chemotherapy: tumor recurrence and metastasis in a competitive environment. Bull Math Biol. 1996;58:425–47.
35. Gatenby RA, Vincent TL. Application of quantitative models from population biology and evolutionary game theory to tumor therapeutic strategies. Mol Can-cer Ther. 2003;2:919–27.
36. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep. 1986;70:163–9.
37. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63:1727–33.
38. Goldie JH, Coldman AJ. Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep. 1983;67:923–31.
39. Iwasa Y, Michor F, Nowak MA. Evolutionary dynamics of escape from biomedical intervention. Proc Biol Sci. 2003;270:2573–8.
40. Komarova NL, Wodarz D. Combination therapies against chronic myeloid leukemia: short-term versus long-term strategies. Cancer Res. 2009;69:4904–10.
41. Foo J, Michor F. Evolution of resistance to anti-cancer therapy during general dosing schedules. J Theor Biol. 2010;263:179–88.
42. Durrett R, Foo J, Leder K, Mayberry J, Michor F. Evolutionary dynamics of tumor progression with random fitness values. Theor Popul Biol. 2010;78:54–66.
43. Mumenthaler SM, Foo J, Leder K, et al. Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Mol Pharm. 2011;8:2069–79.
44. Gerlee P, Anderson AR. Diffusion-limited tumour growth: simulations and analysis. Math Biosci Eng. 2010;7:385–400.
45. Macklin P, McDougall S, Anderson AR, Chaplain MA, Cristini V, Lowengrub J. Multiscale modelling and nonlinear simulation of vascular tumour growth. J Math Biol. 2009;58:765–798.
46. Chaplain MA. Mathematical Modeling of Tumor Growth (Interdisciplinary Applied Mathematics). Berlin: Springer; 2007.
47. Chmielecki J, Foo J, Oxnard GR, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med. 2011;3:90 ra59.
48. Foo J, Chmielecki J, Pao W, Michor F. Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. J Thoracic Oncol. 2012;7:1583–93.
49. Jackson TL, Byrne HM. A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy. Math Biosci. 2000;164:17–38.
50. Greulich P, Waclaw B, Allen RJ. Mutational pathway determines whether drug gradients accelerate evolution of drug-resistant cells. Phys Rev Lett. 2012;109:088-101.
51. Hermsen R, Deris JB, Hwa T. On the rapidity of antibiotic resistance evolution facilitated by a concentration gradient. Proc Natl Acad Sci U S A. 2012;109:10775–80.
52. Graves EE, Maity A, Le QT. The tumor microenvironment in non-small-cell lung cancer. Semin Radiat Oncol. 2010;20:156–63.
53. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501:346–54.
54. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891–9.
55. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99:1441–54.
56. Murphy WK, Fossella FV, Winn RJ. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst. 1993;85:384–8.
57. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol. 2004;14:198–206.
58. Vaupel P, Hockel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal. 2007;9:1221–35.
59. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26:225–39.
60. Ohashi K, Sequist LV, Arcila ME, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A. 2012;109:E2127–33.
61. Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer. 2006;6(12):924–35.
62. Das Thakur M, Stuart DD. The evolution of melanoma resistance reveals therapeutic opportunities. Cancer Res. 2013;73:6106–10.
63. Foo J, Michor F. Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. PLoS Comput Biol. 2009;5:e1000557.
64. Wise DR, Ward PS, Shay JE, et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci U S A. 2011;108:19611–6.
65. Metallo CM. Expanding the reach of cancer metabolomics. Cancer Prev Res (Phila). 2012;5:1337–40.
66. Guillaumond F, Leca J, Olivares O, et al. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A. 2013;110(10):3919–24.
67. Giantonio BJ, Catalano PJ, Meropol NJ, Eastern Cooperative Oncology Group Study E3200, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–44.
68. Meng F, Evans JW, Bhupathi D, et al. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther. 2012;11:740–51.
69. Stresing V, Daubine F, Benzaid I, Monkkonen H, Clezardin P. Bisphosphonates in cancer therapy. Cancer Lett. 2007;257:16–35.
70. Castellano D, Sepulveda JM, García-Escobar I, Rodriguez-Antolín A, Sundlöv A, Cortes-Funes H. The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist. 2011;16:136–45.
71. Alonzi R, Padhani AR, Maxwell RJ, et al. Carbogen breathing increases prostate cancer oxygenation: a translational MRI study in murine xenografts and humans. Br J Cancer. 2009;100:644–8.
72. Powell ME, Collingridge DR, Saunders MI, Hoskin PJ, Hill SA, Chaplin DJ. Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations. Radiother Oncol. 1999;50:167–71.
73. Hall EJG, Giaccia AJ. Radiobiology for the Radiologist. 7th ed. Hoboken: Wiley; 2011.